vs
CPI AEROSTRUCTURES INC（CVU）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CPI AEROSTRUCTURES INC的1.6倍（$30.3M vs $19.4M），CPI AEROSTRUCTURES INC净利率更高（3.6% vs -221.3%，领先224.9%），REGENXBIO Inc.同比增速更快（43.0% vs -10.8%），CPI AEROSTRUCTURES INC自由现金流更多（$-2.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.9%）
CPI航空结构公司（简称CPI Aero）总部位于美国纽约州埃德伍德国，是一家专业承接定制订单的飞机零部件制造商，专注为航空领域客户供应航空结构组件。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CVU vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$19.4M
营收增速更快
RGNX
高出53.8%
-10.8%
净利率更高
CVU
高出224.9%
-221.3%
自由现金流更多
CVU
多$50.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.4M | $30.3M |
| 净利润 | $691.8K | $-67.1M |
| 毛利率 | 20.3% | — |
| 营业利润率 | 6.4% | -190.0% |
| 净利率 | 3.6% | -221.3% |
| 营收同比 | -10.8% | 43.0% |
| 净利润同比 | -28.8% | -31.2% |
| 每股收益（稀释后） | $0.04 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVURGNX
| Q4 25 | $19.4M | $30.3M | ||
| Q3 25 | $19.3M | $29.7M | ||
| Q2 25 | $15.2M | $21.4M | ||
| Q1 25 | $15.4M | $89.0M | ||
| Q4 24 | $21.8M | $21.2M | ||
| Q3 24 | $19.4M | $24.2M | ||
| Q2 24 | $20.8M | $22.3M | ||
| Q1 24 | $19.1M | $15.6M |
净利润CVURGNX
| Q4 25 | $691.8K | $-67.1M | ||
| Q3 25 | $1.1M | $-61.9M | ||
| Q2 25 | $-1.3M | $-70.9M | ||
| Q1 25 | $-1.3M | $6.1M | ||
| Q4 24 | $971.5K | $-51.2M | ||
| Q3 24 | $749.7K | $-59.6M | ||
| Q2 24 | $1.4M | $-53.0M | ||
| Q1 24 | $168.2K | $-63.3M |
毛利率CVURGNX
| Q4 25 | 20.3% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 4.4% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | 20.0% | 70.2% | ||
| Q3 24 | 21.7% | 48.8% | ||
| Q2 24 | 24.6% | 52.5% | ||
| Q1 24 | 18.6% | 72.6% |
营业利润率CVURGNX
| Q4 25 | 6.4% | -190.0% | ||
| Q3 25 | 9.1% | -176.3% | ||
| Q2 25 | -13.1% | -296.3% | ||
| Q1 25 | -7.7% | 13.6% | ||
| Q4 24 | 9.5% | -242.1% | ||
| Q3 24 | 7.6% | -256.6% | ||
| Q2 24 | 11.2% | -251.3% | ||
| Q1 24 | 4.4% | -408.8% |
净利率CVURGNX
| Q4 25 | 3.6% | -221.3% | ||
| Q3 25 | 5.8% | -208.3% | ||
| Q2 25 | -8.7% | -331.8% | ||
| Q1 25 | -8.6% | 6.8% | ||
| Q4 24 | 4.5% | -241.3% | ||
| Q3 24 | 3.9% | -246.3% | ||
| Q2 24 | 6.8% | -237.7% | ||
| Q1 24 | 0.9% | -405.4% |
每股收益（稀释后）CVURGNX
| Q4 25 | $0.04 | $-1.30 | ||
| Q3 25 | $0.09 | $-1.20 | ||
| Q2 25 | $-0.10 | $-1.38 | ||
| Q1 25 | $-0.10 | $0.12 | ||
| Q4 24 | $0.08 | $-0.99 | ||
| Q3 24 | $0.06 | $-1.17 | ||
| Q2 24 | $0.11 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $25.8M | $102.7M |
| 总资产 | $75.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资CVURGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务CVURGNX
| Q4 25 | $0 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $26.5K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CVURGNX
| Q4 25 | $25.8M | $102.7M | ||
| Q3 25 | $25.0M | $161.5M | ||
| Q2 25 | $23.8M | $213.7M | ||
| Q1 25 | $24.9M | $274.2M | ||
| Q4 24 | $25.9M | $259.7M | ||
| Q3 24 | $24.9M | $301.4M | ||
| Q2 24 | $24.1M | $348.3M | ||
| Q1 24 | $22.5M | $390.7M |
总资产CVURGNX
| Q4 25 | $75.2M | $453.0M | ||
| Q3 25 | $74.1M | $525.2M | ||
| Q2 25 | $72.3M | $581.0M | ||
| Q1 25 | $65.4M | $490.9M | ||
| Q4 24 | $68.0M | $466.0M | ||
| Q3 24 | $68.9M | $519.1M | ||
| Q2 24 | $70.2M | $569.4M | ||
| Q1 24 | $70.8M | $629.2M |
负债/权益比CVURGNX
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -10.8% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | -3.03× | — |
| 过去12个月自由现金流最近4个季度 | $-5.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CVURGNX
| Q4 25 | $-2.1M | $-52.3M | ||
| Q3 25 | $212.1K | $-56.0M | ||
| Q2 25 | $-596.3K | $-49.3M | ||
| Q1 25 | $-2.7M | $33.6M | ||
| Q4 24 | $4.4M | $-31.6M | ||
| Q3 24 | $715.1K | $-40.5M | ||
| Q2 24 | $-591.7K | $-45.5M | ||
| Q1 24 | $-960.5K | $-55.5M |
自由现金流CVURGNX
| Q4 25 | $-2.1M | $-52.8M | ||
| Q3 25 | $211.1K | $-56.5M | ||
| Q2 25 | $-599.8K | $-49.7M | ||
| Q1 25 | $-2.8M | $32.6M | ||
| Q4 24 | $4.3M | $-32.7M | ||
| Q3 24 | $586.9K | $-40.9M | ||
| Q2 24 | $-746.9K | $-46.0M | ||
| Q1 24 | $-1.0M | $-56.0M |
自由现金流率CVURGNX
| Q4 25 | -10.8% | -174.0% | ||
| Q3 25 | 1.1% | -189.9% | ||
| Q2 25 | -4.0% | -232.8% | ||
| Q1 25 | -18.1% | 36.6% | ||
| Q4 24 | 19.9% | -154.2% | ||
| Q3 24 | 3.0% | -168.9% | ||
| Q2 24 | -3.6% | -206.2% | ||
| Q1 24 | -5.3% | -358.5% |
资本支出强度CVURGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 0.3% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.7% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率CVURGNX
| Q4 25 | -3.03× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 4.53× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.42× | — | ||
| Q1 24 | -5.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVU
| Government Subcontracts | $16.4M | 85% |
| Commercial Contracts | $2.3M | 12% |
| Prime Government Contracts | $725.8K | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
